Moleculin Biotech Enrolls 45 Subjects in Clinical Trial

Moleculin Biotech announced that the company has enrolled 45 subjects in its ongoing clinical trial, reaching a key milestone in the development of its therapeutic candidate. CEO Walter Klemp confirmed the enrollment figure during a recent virtual investor presentation, where he outlined the current status of the study and the implications of the patient data collected thus far.

The company currently manages this trial to evaluate the safety and efficacy of its lead compound in a clinical setting. By reaching this 45-subject threshold, Moleculin moves forward with its data gathering process, which aims to provide further insight into the drug’s performance. The company intends to use the information gathered from these participants to inform future regulatory steps and trial design. Moleculin continues to monitor the progress of these subjects as the study proceeds according to its established protocol.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 4, 2026

Author

GOAI